January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
December 2025 in “Cureus” Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
July 2025 in “Journal of Investigative Dermatology” IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
June 2025 in “Journal of Cosmetic Dermatology” Dutasteride 0.5 mg/day is the most effective treatment for male pattern hair loss.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules from plants may help treat hair loss.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules from plants may help treat hair loss.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
April 2025 in “Archives of Dermatological Research” H19 may help prevent hair loss by keeping hair cells young.
March 2025 in “International Journal For Multidisciplinary Research” Computational techniques can improve drug development for treating certain conditions.
February 2025 in “Iranian journal of pharmaceutical research”
February 2025 in “Journal of Pre-Clinical and Clinical Research” The combination of finasteride, dutasteride, and minoxidil is generally safe for treating male hair loss with minimal side effects.
September 2024 in “Health of Man” Low-dose dutasteride effectively and safely promotes hair growth in men with androgenetic alopecia.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
April 2024 in “Expert opinion on emerging drugs” New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
June 2023 in “Journal of Cosmetic Dermatology” Finasteride 5mg daily is the most effective for female pattern hair loss, with higher doses of treatments generally more effective.
May 2023 in “Acta Oncologica” 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
The document suggests that drugs for prostate issues might cause lasting sexual, mental, and physical health problems due to blood vessel damage in the penis.
October 2021 in “Rheumatology Science and Practice” TNF-α inhibitors may cause complete hair loss in some patients with ankylosing spondylitis.
September 2021 in “World journal of urology” The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.